Announced mere weeks after Biohaven sold off rights to the therapy, opakalim, the halt affects a study some analysts believe is necessary to support a potential approval.
An article from
Dive Brief
Announced mere weeks after Biohaven sold off rights to the therapy, opakalim, the halt affects a study some analysts believe is necessary to support a potential approval.
Published Sept. 10, 2026
Sarah Silbiger via Getty Images
An epilepsy study of the experimental drug called BHV-7000 was paused after regulators requested more information about…
Biohaven stock plummeted Thursday after the company paused enrollment in a midstage study of its seizure treatment.
Biohaven reports an FDA partial clinical hold on BHV-7000 new enrollment while keeping pivotal epilepsy trial data readouts on…
Faced with a dwindling bank account after a series of research setbacks, Biohaven is letting go of its most advanced experimental…
Biohaven (BHVN) shares fall as BofA downgrades the stock to Underperform, citing a risky profile ahead of key epilepsy trial data.
SK Biopharmaceuticals is staking nearly $800 million on rights to an epilepsy treatment from US biotech firm Biohaven, the…
Why Is Biohaven Stock Tumbling Today? - Biohaven (NYSE:BHVN)
